VisionGate, Inc news
For many families, November signals the start of the holiday season. It is a special time to gather with loved ones and check-in to make sure everyone is happy and healthy. November is also lung cancer awareness month.
VisionGate wants to help you, your family and loved ones learn more about who is at risk, the impact, and the types of lung cancer. Because keeping yourself informed about the risks and early detection options can prov
VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC), 23-26 September in Toronto, Canada. These studies demonstrate important new morphometric detection findings of the Cell-CT™ platform and the LuCED® lung test. These findings promote new disease interception capability for the detection of early s
VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, today presented a breakthrough research study demonstrated its CellCT™ platform can detect subtle changes in cellular and nuclear morphology of cancer-associated cells (CACs) as a result of the cancer field effect. These non-cancerous cells have been affected by the presence of the cancer cells and have undergone structural changes which include alterations in nuclear chromatin compaction – a phenomenon
VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce that new lung cancer 3D cellular imaging research findings will be presented at the upcoming 2018 American Association of Cancer Research (AACR) annual meeting in Chicago, Illinois from April 14-18, 2018.
The abstract presentation includes a breakthrough research study using the Company’s Cell-CT™ platform 3D cellular imaging technology to detect subtle alterations in
VisionGate, a clinical stage oncology pharmaceutical and diagnosticscompany, is pleased to announce today the advancement of its breakthrough technology Cell-CT platform. The first shipment of commercial-capable Cell-CT systems were delivered to VisionGate’s clinical laboratory in Phoenix, Arizona earlier this year, setting the stage for the company’s advancement.
“I am pleased to announce that after years of development and refinement, VisionGate’s proprietary